Literature DB >> 3516533

Renal prostaglandins in cirrhosis of the liver.

C Guarner, I Colina, F Guarner, J Corzo, J Prieto, F Vilardell.   

Abstract

Urinary prostaglandin excretion was studied in 42 patients with liver cirrhosis and in nine control subjects on restricted sodium intake and on bed rest. Creatinine clearance (CCr), sodium excretion (UNaV), plasma renin activity (PRA) and plasma aldosterone were also evaluated. Patients without ascites and ascitic patients without renal failure showed increased urinary excretion of immunoreactive 6-ketoprostaglandin F1 alpha (i6-keto-PGF1 alpha), prostaglandin E2 (iPGE2) and thromboxane B2 (iTXB2) when compared with controls, while immunoreactive PGF2a (iPGF2 alpha) levels did not differ from those in the control group. Patients with functional renal failure (FRF) presented a significant reduction of vasodilator prostaglandins but urinary excretion of iTXB2 was higher than in controls. On the whole, cirrhotic patients with higher urinary excretion of prostaglandins had normal or nearly normal PRA and aldosterone levels. i6-keto-PGF1 alpha and iPGE2 inversely correlated with PRA and aldosterone. The relationship between i6-ketoPGF alpha alpha and CCr was found to be highly significant in cirrhotic patients but not in the control group. On the other hand, iPGE2 significantly correlated with UNaV and with the fractional excretion of sodium (FENa). We concluded that: (a) enhanced renal prostaglandin synthesis in cirrhosis, inversely related to PRA and aldosterone, may be dependent on volume status; and (b) preserved renal function in these patients is associated with the ability to synthesize prostacyclin and PGE2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516533     DOI: 10.1042/cs0700477

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

2.  Hepatorenal syndrome.

Authors:  Charles K F Ng; Michael H M Chan; Morris H L Tai; Christopher W K Lam
Journal:  Clin Biochem Rev       Date:  2007-02

3.  Renal function in fulminant hepatic failure: haemodynamics and renal prostaglandins.

Authors:  F Guarner; R D Hughes; A E Gimson; R Williams
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

Review 4.  Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?

Authors:  Amirali Masoumi; Fernando Ortiz; Jai Radhakrishnan; Robert W Schrier; Paolo C Colombo
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

5.  Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis.

Authors:  J Vilaseca; A Salas; F Guarner; R Rodríguez; M Martínez; J R Malagelada
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

Review 6.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.